2017 Cell & Gene Meeting on the Mesa featuring Renova Therapeutics CEO & Co-founder as speaker
SAN DIEGO, Calif., Sept. 28, 2017 /PRNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the company's CEO and Co-founder, Jack W. Reich, Ph.D., will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 4-6 in La Jolla, California.
This conference is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing the opportunity for participants to establish key relationships and accelerate business development.
Organized by the Alliance for Regenerative Medicine and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The event's Partnering Forum on October 4-5 features more than 70 dedicated company presentations in addition to 90 panelists and featured speakers.
The following are specific details regarding Dr. Reich's presentation at the conference:
| Event: |
2017 Cell & Gene Meeting on the Mesa – Partnering Forum |
| Date: |
Wednesday, Oct. 4 |
| Time: |
10:45 a.m. |
| Location: |
Estancia La Jolla Hotel & Spa |
A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM's website shortly after the event.
Please visit www.meetingonthemesa.com/ for full information, including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only.
About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for heart failure and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with heart failure. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.
SOURCE Renova Therapeutics
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article